Newsroom

LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, presented scientific results on novel therapies, treatment strategies, and approaches to managing side effects and complications for blood cancer patients at the 2025 American Society of Hematology (ASH) conference in Orland...

SAN CARLOS, Californie--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq : ONC ; HKEX : 06160 ; SSE : 688235), une société mondiale d'oncologie, annonce aujourd'hui de nouvelles données sur le sonrotoclax, un inhibiteur de BCL2 expérimental de nouvelle génération, démontrant un bénéfice clinique significatif en monothérapie et en combinaison contre des tumeurs malignes à cellules B. Ces données ont été présentées lors de la 67e réunion annuelle de l'American Society of Hematology (ASH) à Orlando,...

NEW YORK--(BUSINESS WIRE)--Last November, the Ministry of Tourism of the Dominican Republic marked a milestone year for the country’s tourism by hosting more than 800 guests—including travel agents, tour operators, airline and cruise line executives, and travel industry leaders—at the iconic Cipriani Wall Street. The event followed the announcement of remarkable tourism results, with 3,730,852 nonresident air travelers from the United States visiting the Dominican Republic between January and O...

カリフォルニア州サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- グローバルなオンコロジー企業であるBeOne Medicines Ltd.（Nasdaq: ONC、HKEX: 06160、SSE: 688235）は、次世代の治験中BCL2阻害薬であるソンロトクラックスについて、B細胞悪性腫瘍全体にわたり単剤療法および併用療法のいずれにおいても臨床的に意義のある有益性を示した新たなデータを発表しました。これらのデータは、フロリダ州オーランドで開催された第67回米国血液学会（ASH）年次総会・展示会で発表されました。今回の5件の発表では、前治療歴の多い再発／難治性（R/R）マントル細胞リンパ腫（MCL）患者における持続的な奏効に加え、未治療の慢性リンパ性白血病（CLL）患者においてソンロトクラックスをベースとする併用療法により、深く迅速かつ持続的な検出不能微小残存病変（uMRD）の達成率が示されており、本剤がB細胞悪性腫瘍における基盤的治療薬となる可能性を浮き彫りにしています。 「今回、ASH 2025で発表しているデータは、次世代BCL2阻害薬としてのソンロ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will present new data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9th in Orlando, Florida. SonoThera’s oral presentation focuses on the safe delivery of DNA expression vectors to the liver in non-human primate (NHP) models using...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncología, anunció hoy nuevos datos sobre Sonrotoclax, un inhibidor de BCL2 de próxima generación en investigación, que muestran beneficios clínicos significativos tanto en monoterapia como en combinaciones para diversas neoplasias de células B. Estos resultados se presentaron en la 67ª Reunión y Exposición Anual de la Sociedad Estadounidense de Hematología (ASH, American Soc...

CINCINNATI--(BUSINESS WIRE)--Today, Fifth Third Bancorp announced the declaration of cash dividends on its common shares, Series H preferred shares, Series I preferred shares, Series J preferred shares, Series K preferred shares, and Class B Series A preferred shares. Fifth Third Bancorp (Nasdaq: FITB) today declared a cash dividend on its common shares of $0.40 per share for the fourth quarter of 2025. The dividend is payable on January 15, 2026 to shareholders of record as of December 31, 202...

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球腫瘤醫學公司BeOne Medicines Ltd.（Nasdaq：ONC；HKEX：06160；SSE：688235）日公布了其下一代研發中BCL2抑制劑sonrotoclax的最新數據，顯示該藥物作為單藥或聯合治療在多種B細胞惡性腫瘤中具備重要的臨床效益。這些數據於佛羅里達州奧蘭多舉行的第67屆美國血液學會（ASH）年會暨展覽中發表。五項報告凸顯sonrotoclax在經大量前線治療後復發/難治（R/R）的套細胞淋巴瘤（MCL）患者中展現持久反應，此外，其他研究結果顯示，在初治慢性淋巴細胞性白血病（CLL）患者中，基於sonrotoclax的聯合療法能達成深度、快速且持續的不可偵測微小殘留病灶（uMRD）率，進一步突顯此藥物的基礎潛力。 BeOne血液腫瘤首席醫學官Amit Agarwal醫學博士表示：「我們在ASH 2025發表的數據，正在重新定義醫師對sonrotoclax作為下一代BCL2抑制劑的期待。我們的數據顯示，sonrotoclax 在其他藥物未能奏效之處取得成功，無論在R/R CLL還是MC...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Axle Point Capital, a Newport Beach private equity group, successfully closes its first transaction, investing in Odyssey Space Research, LLC....

OAKLAND, Calif.--(BUSINESS WIRE)--Throughout December, Stephen and Ayesha Curry’s Eat. Learn. Play. Foundation is bringing the joy of reading to thousands of Oakland elementary students through the 13th annual Christmas with the Currys, a beloved holiday tradition rooted in generosity, community and joyful learning. From December 1-19, the Oakland-based foundation will host free, holiday-themed book fairs at 47 public elementary schools across the Oakland Unified School District (OUSD), giving...